New Jersey's federal courts are in the midst of a surge in patent litigation, driven by pharmaceutical companies' claims of infringement against generic-drug producers.
Plaintiffs filed seven patent suits in the District of New Jersey from May 20-26, representing a major escalation when compared with the average rate of one new patent suit per week. And the surge continued in the period from May 26-30, when another three patent suits were filed.
All but one of the 10 cases were brought by holders of drug patents seeking to stop the production of generic versions of their products.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
Charles Toutant
Charles Toutant is a litigation writer for the New Jersey Law Journal.
